How to use an EpiPen
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
"Multiple System Atrophy Clinical Trials" Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others. (Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market. As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook Some of the key takeaways from the Multiple System Atrophy Pipeline Report: Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years. are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy. In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA). In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025. Multiple System Atrophy Overview Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders. Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis. Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life. Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment- Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include: NM-402: Neuramedy Co.,Ltd Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences ProMIS Neurosciences ENT-01: Enterin Inc. Enterin Inc. NC-2500: Nippon Chemiphar Nippon Chemiphar CS10BR05: CORESTEM, Inc CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc. Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines Kainos Medicines ATH434: Alterity Therapeutics Alterity Therapeutics Lu AF82422: H. Lundbeck A/S H. Lundbeck A/S Verdiperstat: Biohaven, Ltd Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc Multiple System Atrophy Route of Administration Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Multiple System Atrophy Molecule Type Multiple System Atrophy Products have been categorized under various Molecule types, such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Multiple System Atrophy Pipeline Therapeutics Assessment Multiple System Atrophy Assessment by Product Type Multiple System Atrophy By Stage and Product Type Multiple System Atrophy Assessment by Route of Administration Multiple System Atrophy By Stage and Route of Administration Multiple System Atrophy Assessment by Molecule Type Multiple System Atrophy by Stage and Molecule Type DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies Some of the key companies in the Multiple System Atrophy Therapeutics Market include: Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others. Multiple System Atrophy Pipeline Analysis: The Multiple System Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment. Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies Multiple System Atrophy Pipeline Market Drivers Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market. Multiple System Atrophy Pipeline Market Barriers However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth. Scope of Multiple System Atrophy Pipeline Drug Insight Coverage: Global Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials Table of Contents 1. Multiple System Atrophy Report Introduction 2. Multiple System Atrophy Executive Summary 3. Multiple System Atrophy Overview 4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment 5. Multiple System Atrophy Pipeline Therapeutics 6. Multiple System Atrophy Late Stage Products (Phase II/III) 7. Multiple System Atrophy Mid Stage Products (Phase II) 8. Multiple System Atrophy Early Stage Products (Phase I) 9. Multiple System Atrophy Preclinical Stage Products 10. Multiple System Atrophy Therapeutics Assessment 11. Multiple System Atrophy Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Multiple System Atrophy Key Companies 14. Multiple System Atrophy Key Products 15. Multiple System Atrophy Unmet Needs 16 . Multiple System Atrophy Market Drivers and Barriers 17. Multiple System Atrophy Future Perspectives and Conclusion 18. Multiple System Atrophy Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
CTV News
38 minutes ago
- CTV News
Air quality concerns in southern Ontario due to drifting wildfire smoke
The Kitchener, Ont. skyline was partially obscured by smoke in this image from June 5, 2025. Environment Canada advised people living in southern Ontario to stay indoors Monday as air quality dropped to unhealthy levels. The agency uses a scale ranging from one to 10 to determine air quality risk. It rose to seven on Monday, indicating a 'high risk,' as wildfire smoke drifted south from northern Ontario and western provinces. 'I definitely canceled a cycling trip this morning,' said Ze'ev Gedalof, a professor in the Geography, Environment and Geomatics department at the University of Guelph. IQAir, a Swiss air quality company, backed up Environment Canada's findings. At one point on Monday, Kitchener was ranked 4th in the province for poor air quality. The company said the 'Auditorium Neighbourhood' had the worst of it at 9:45 a.m., with an air quality index of 188 out of 210, which is considered 'unhealthy.' 'When you compound this with the heat, you're just asking for a respiratory emergency,' said Gedalof. 'If you don't have to go outdoors, don't do it.' According to Region of Waterloo Public Health, residents with preexisting health conditions and older people are most affected by poor air quality and should reconsider outdoor activities. Anyone who develops a cough or irritated throat may also want to head indoors. While conditions have improved since Monday morning, experts said it's still important to check air quality reports throughout the day. 'Most important thing when it comes to poor air quality and to wildfire smoke, is that it can change throughout the day,' said Brandie Bevis, a health promotion and research analyst at Region of Waterloo Public Health. 'You want to make sure you go to the Air Quality Health Index tool for the Kitchener-Waterloo Region.' That section reflects the latest data for the entire region. 'From there you'll be able to monitor whether or not you want to be changing your plans for the day or whether or not you are taking a little bit more concern about how you are feeling, how is your body managing right now with the heat and with the poor air quality,' Bevis continued. 'So, really listening to your body and your symptoms, if you need to take a break, if you're finding that it's impacting how you're breathing maybe reduce your activity, stay in an air-conditioned space.' The region has also identified 57 'clean air' locations around the community. They are the same spaces used as warming centres in the winter and cooling centres in the summer. 'Anyone can go during regular business hours to get relief from the heat and the poor air quality. It's really important to take breaks from both,' Bevis said. She also urged people to check in on family, friends and neighbours who don't have air conditioning, live alone or are at-risk for developing complications. Gedalof said if you do need to work outside, a properly fitted N95 mask can help filter out some of the toxins. 'There is no safe level of wildfire smoke, it's full of all kinds of toxic compounds,' he explained. 'The haze is mostly PM10. It's 10 microns in size and our noses are actually pretty good at filtering that out. It's what we can't see that's dangerous, so PM2.5, up to two-and-a-half microns across. It's effectively invisible. And when you breathe that in, it's a bit like asbestos. It goes deep into your lungs, and it just stays there forever.' Health risks Environment Canada said people with heart and lung conditions are most affected by poor air quality. Other vulnerable groups include seniors, pregnant people, infants, children, outdoor workers and those with chronic illnesses. Air pollution can cause symptoms such as mild eye, nose and throat irritation, headaches or a mild cough. In more severe cases, people may experience wheezing, tightness in the chest or a persistent cough. Anyone experiencing severe symptoms should seek medical attention immediately.
National Post
40 minutes ago
- National Post
Alberta reports 1,314 confirmed measles cases since March, surpassing U.S. number
Article content She noted that it's expected for every 1,000 cases, one to three people will die. Article content 'Quite a large number — maybe even as many as one in five — will get a bacterial infection after measles,' she said. Article content 'That's not nothing, that's a big deal.' Article content Opposition NDP Leader Naheed Nenshi said the United Conservative government should step up public health awareness efforts before Alberta starts seeing its own severe outcomes. Article content 'In a time where we have a massive public health outbreak, we are seeing absolute silence from this government,' Nenshi said. Article content 'This is absolute dereliction of duty and it has very real consequences on children who are getting very, very ill.' Article content Preventative Health Services Minister Adriana LaGrange's office did not immediately respond to questions Monday. Article content Saxinger also said she thought recent actions taken by U.S. President Donald Trump could be undermining the trustworthiness of U.S. data. Article content In March, the Trump administration moved to cut more than US$11 billion in public health funding across dozens of states, though in May a federal judge granted an injunction to block the cuts after 23 states filed a lawsuit. Article content Article content 'I'm not sure … the data infrastructure is as reliable as it used to be,' Saxinger said about the United States. Article content 'When you introduce a lot of chaos and disruption into a system that really relies on an organizational structure to make things happen properly, there's going to be problems.' Article content The two professors said it's unlikely Alberta or other provinces dealing with measles outbreaks will be able to get transmission under control before the fall, which is when Canada could lose its long-held measles eradication status. Article content Jenne said losing the status might not mean much for many Albertans when it comes to day-to-day life, though it could mean other countries might implement travel recommendations and vaccine requirements for those visiting Canada. Article content 'Those things can impact things as far-ranging as tourism to amateur sport visits to even business meetings if Canada is seen as an infection risk to other countries' populations,' he said. Article content 'This is something we really need to avoid, but it is not looking very likely that we will be able to avoid it, at least in the short term.' Article content
